EGIS Pharmaceuticals PLC

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
The novel PREDYSTIC® Infliximab RA diagnostic test identifies bio-naïve patients with RA who are likely responders to infliximab treatment. The test is designed to use before treatment initiation, so it predicts drug response. This is a clinically validated blood test currently under CE-IVD registration.

EGIS is one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Hungary
Year Founded:
1913
Main Therapeutic Focus:
Lead Product in Development:
PREDYSTIC®
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
International Diagnostic License-Out Manager
EGIS Pharmaceuticals